Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TMO 
Thermo Fisher Scientific Inc (TMO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: TMO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
31 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $612.73
1 Year Target Price $612.73
| 18 | Strong Buy |
| 7 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 14.89% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 210.04B USD | Price to earnings Ratio 32.15 | 1Y Target Price 612.73 |
Price to earnings Ratio 32.15 | 1Y Target Price 612.73 | ||
Volume (30-day avg) 31 | Beta 0.78 | 52 Weeks Range 385.11 - 609.27 | Updated Date 10/31/2025 |
52 Weeks Range 385.11 - 609.27 | Updated Date 10/31/2025 | ||
Dividends yield (FY) 0.30% | Basic EPS (TTM) 17.3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-22 | When Before Market | Estimate 5.5 | Actual 5.79 |
Profitability
Profit Margin 15.02% | Operating Margin (TTM) 19.33% |
Management Effectiveness
Return on Assets (TTM) 5.03% | Return on Equity (TTM) 13.12% |
Valuation
Trailing PE 32.15 | Forward PE 21.28 | Enterprise Value 227070259040 | Price to Sales(TTM) 4.8 |
Enterprise Value 227070259040 | Price to Sales(TTM) 4.8 | ||
Enterprise Value to Revenue 5.25 | Enterprise Value to EBITDA 20.16 | Shares Outstanding 377612121 | Shares Floating 377123040 |
Shares Outstanding 377612121 | Shares Floating 377123040 | ||
Percent Insiders 0.16 | Percent Institutions 91.97 |
Upturn AI SWOT
Thermo Fisher Scientific Inc
Company Overview
History and Background
Thermo Fisher Scientific Inc. was formed in 2006 through the merger of Thermo Electron and Fisher Scientific. Thermo Electron was founded in 1956, focusing on analytical instruments, while Fisher Scientific, founded in 1902, was a major supplier of laboratory equipment and chemicals. The merger created a comprehensive life sciences and laboratory solutions company.
Core Business Areas
- Life Sciences Solutions: Provides reagents, instruments, and consumables for biological and medical research, including cell culture, genetic analysis, and protein analysis.
- Analytical Instruments: Offers instruments and related services for chromatography, mass spectrometry, and other analytical techniques used in various industries.
- Specialty Diagnostics: Develops and manufactures diagnostic test kits, reagents, and instruments for clinical laboratories and healthcare providers.
- Laboratory Products and Biopharma Services: Provides a wide range of laboratory equipment, chemicals, and consumables, as well as biopharmaceutical services such as drug development and manufacturing.
Leadership and Structure
The current CEO is Marc N. Casper. The company operates with a divisional structure aligned with its four core business areas, reporting to a corporate headquarters.
Top Products and Market Share
Key Offerings
- Mass Spectrometers: Thermo Fisher is a leading manufacturer of mass spectrometers, used in drug discovery, environmental monitoring, and food safety testing. Competitors include Agilent (A), Bruker (BRKR), and Waters (WAT). Thermo Fisher holds an estimated ~30% market share in mass spectrometry market.
- Chromatography Systems: Provides chromatography solutions for various applications. Agilent (A) and Waters (WAT) are major competitors. Market is competitive with a few large players and many smaller specialized players.
- Cell Culture Products: Offers cell culture media, reagents, and instruments for cell-based research and biopharmaceutical manufacturing. Competitors are Danaher (DHR) (Cytiva), Merck KGaA.
- PCR Technology: Thermo Fisher provides qPCR instruments and kits for genetic analysis. Competitors include Bio-Rad (BIO) and Roche (RHHBY).
Market Dynamics
Industry Overview
The life sciences and diagnostics industry is characterized by innovation, regulatory oversight, and increasing demand for personalized medicine. Key drivers include aging populations, growing healthcare spending, and advancements in genomics and proteomics.
Positioning
Thermo Fisher Scientific Inc. holds a leading position due to its comprehensive product portfolio, global reach, and strong brand reputation. Its competitive advantages include its scale, innovation capabilities, and customer relationships.
Total Addressable Market (TAM)
The total addressable market for life sciences tools and services is estimated to be several hundred billion dollars annually. Thermo Fisher is well positioned to capture a significant share of this market, with a TAM around $80B annually.
Upturn SWOT Analysis
Strengths
- Comprehensive product portfolio
- Global presence and distribution network
- Strong brand reputation
- Significant R&D investment
- Effective acquisition strategy
Weaknesses
- High levels of debt from acquisitions
- Exposure to economic cycles
- Complexity of managing a large, diverse organization
- Integration challenges from acquisitions
Opportunities
- Growing demand for personalized medicine
- Expansion in emerging markets
- Technological advancements in genomics and proteomics
- Increased outsourcing in biopharmaceutical manufacturing
- Increased investment in R&D globally
Threats
- Increased competition
- Pricing pressure from generic manufacturers
- Regulatory changes and compliance requirements
- Economic downturns
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- DHR
- WAT
- A
- BIO
Competitive Landscape
Thermo Fisher Scientific Inc. has a broad product portfolio and global reach, giving it a competitive advantage over smaller, more specialized players. Danaher (DHR) is a major competitor with a similar diversified approach. Agilent (A) and Waters (WAT) are strong in specific instrument markets. Bio-Rad (BIO) competes with life science products.
Major Acquisitions
PPD
- Year: 2021
- Acquisition Price (USD millions): 17400
- Strategic Rationale: PPD acquisition enhances Thermo Fisher's clinical research services, creating a comprehensive offering across the drug development process. This strengthened their services business with high growth and larger margins.
Growth Trajectory and Initiatives
Historical Growth: Thermo Fisher Scientific Inc. has demonstrated consistent growth through organic expansion and strategic acquisitions.
Future Projections: Analyst estimates predict continued revenue and earnings growth, driven by favorable industry trends and the company's strong market position.
Recent Initiatives: Recent initiatives include investments in R&D, expansion of manufacturing capacity, and strategic acquisitions to strengthen its product portfolio.
Summary
Thermo Fisher Scientific Inc. is a strong player in the life sciences and diagnostics industry, driven by its diversified product portfolio and strategic acquisitions. Its global presence and R&D investments position it well for future growth. However, the company needs to manage its debt levels and navigate increasing competition to maintain its leading position.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Market Research Reports
- Company Website
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Market share data may vary based on different sources and definitions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Thermo Fisher Scientific Inc
Exchange NYSE | Headquaters Waltham, MA, United States | ||
IPO Launch date 1978-01-13 | Chairman, President & CEO Mr. Marc N. Casper | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 125000 | Website https://www.thermofisher.com |
Full time employees 125000 | Website https://www.thermofisher.com | ||
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, as well as diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment includes clinical diagnostics offering liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics offers develops, manufactures, and markets complete blood test systems to support the clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; microbiology offers dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; transplant diagnostics products include human leukocyte antigen typing and testing for organ transplant market; and healthcare market channel offers consumables, diagnostic kits and reagents, equipment, instruments, solutions, and services. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.